|
- PD-1 PD-L1 pathway: current researches in cancer - PMC
Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune responses and promoting self-tolerance through modulating the activity of T-cells, activating apoptosis of antigen-specific T cells and inhibiting apoptosis of regulatory T cells
- Immune Checkpoint Inhibitors and Their Side Effects
PD-1 is a checkpoint protein on immune cells called T cells It normally acts as a type of “off switch” that helps keep the T cells from attacking other cells in the body It does this when it attaches to PD-L1, a protein on some normal (and cancer) cells When PD-1 binds to PD-L1, it basically tells the T cell to leave the other cell alone
- PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond
Only one gene was discovered at that time in a challenging screening experiment in molecular biology, and the gene (or its product) was named programmed death-1 (PD-1), with a hope that it would be somehow involved in the apoptosis-inducing processes of self-reactive immature T cells [1]
- Pathology Outlines - Programmed death-1 (PD-1)
PD-1 highlights a single layer of follicular helper T cells, which surround neoplastic lymphocyte predominant (LP) cells of nodular lymphocyte predominant Hodgkin lymphoma, forming rosettes
- PD-1 PD-L1 pathway: current researches in cancer - PubMed
Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune responses and promoting self-tolerance through modulating the activity of T-cells, activating apoptosis of antigen-specific T cells and inhibiting apoptosis of regulatory T cells
- PD1 and Immunotherapy: What You Need to Know | Dana-Farber
Some of the most effective immunotherapy agents for cancer are drugs known as checkpoint inhibitors, which, by blocking PD-1, PD-L1 and related proteins, give the immune system a go-ahead to attack tumor cells Dana-Farber scientist Gordon Freeman, PhD, and his colleagues played a major role in the development of some of these inhibitors
- PD-1 - abbviescience. com
Programmed death protein 1 (PD-1) is a type 1 cell surface receptor expressed by activated CD4+ and CD8+ T cells, natural killer (NK) T cells, and antigen-presenting cells (APCs) 1,2 The PD-1 receptor has two ligands, programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2), which are mainly expressed on APCs
- Immune Checkpoint Inhibitors - NCI - National Cancer Institute
Checkpoint proteins, such as PD-L1 on tumor cells and PD-1 on T cells, help keep immune responses in check The binding of PD-L1 to PD-1 keeps T cells from killing tumor cells in the body (left panel)
|
|
|